AAAAAA

   
Results: 1-10 |
Results: 10
Neuroprotection by caffeine and A(2A) adenosine receptor inactivation in amodel of Parkinson's disease
Authors: Chen, JF Xu, K Petzer, JP Staal, R Xu, YH Beilstein, M Sonsalla, PK Castagnoli, K Castagnoli, N Schwarzschild, MA
Citation: Jf. Chen et al., Neuroprotection by caffeine and A(2A) adenosine receptor inactivation in amodel of Parkinson's disease, J NEUROSC, 21(10), 2001, pp. NIL_1-NIL_6
Differential sensitivity of mesencephalic neurons to inhibition of phosphatase 2A
Authors: Zeevalk, GD Bernard, LP Manzino, L Sonsalla, PK
Citation: Gd. Zeevalk et al., Differential sensitivity of mesencephalic neurons to inhibition of phosphatase 2A, J PHARM EXP, 298(3), 2001, pp. 925-933
Parallel increases in lipid and protein oxidative markers in several mousebrain regions after methamphetamine treatment
Authors: Gluck, MR Moy, LY Jayatilleke, E Hogan, KA Manzino, L Sonsalla, PK
Citation: Mr. Gluck et al., Parallel increases in lipid and protein oxidative markers in several mousebrain regions after methamphetamine treatment, J NEUROCHEM, 79(1), 2001, pp. 152-160
Pharmacological inactivation of the vesicular monoamine transporter can enhance 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurodegeneration of midbrain dopaminergic neurons, but not locus coeruleus noradrenergic neurons
Authors: German, DC Liang, CL Manaye, KF Lane, K Sonsalla, PK
Citation: Dc. German et al., Pharmacological inactivation of the vesicular monoamine transporter can enhance 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurodegeneration of midbrain dopaminergic neurons, but not locus coeruleus noradrenergic neurons, NEUROSCIENC, 101(4), 2000, pp. 1063-1069
In vitro studies of striatal vesicles containing the vesicular monoamine transporter (VMAT2): Rat versus mouse differences in sequestration of 1-methyl-4-phenylpyridinium
Authors: Staal, RGW Hogan, KA Liang, CL German, DC Sonsalla, PK
Citation: Rgw. Staal et al., In vitro studies of striatal vesicles containing the vesicular monoamine transporter (VMAT2): Rat versus mouse differences in sequestration of 1-methyl-4-phenylpyridinium, J PHARM EXP, 293(2), 2000, pp. 329-335
Inhibition of brain vesicular monoamine transporter (VMAT2) enhances 1-methyl-4-phenylpyridinium neurotoxicity in vivo in rat striata
Authors: Staal, RGW Sonsalla, PK
Citation: Rgw. Staal et Pk. Sonsalla, Inhibition of brain vesicular monoamine transporter (VMAT2) enhances 1-methyl-4-phenylpyridinium neurotoxicity in vivo in rat striata, J PHARM EXP, 293(2), 2000, pp. 336-342
Analysis of VMAT2 binding after methamphetamine or MPTP treatment: Disparity between homogenates and vesicle preparations
Authors: Hogan, KA Staal, RGW Sonsalla, PK
Citation: Ka. Hogan et al., Analysis of VMAT2 binding after methamphetamine or MPTP treatment: Disparity between homogenates and vesicle preparations, J NEUROCHEM, 74(5), 2000, pp. 2217-2220
Role for dopamine in malonate-induced damage in vivo in striatum and in vitro in mesencephalic cultures
Authors: Moy, LY Zeevalk, GD Sonsalla, PK
Citation: Ly. Moy et al., Role for dopamine in malonate-induced damage in vivo in striatum and in vitro in mesencephalic cultures, J NEUROCHEM, 74(4), 2000, pp. 1656-1665
NMDA receptors modulate dopamine loss due to energy impairment in the substantia nigra but not striatum
Authors: Zeevalk, GD Manzino, L Sonsalla, PK
Citation: Gd. Zeevalk et al., NMDA receptors modulate dopamine loss due to energy impairment in the substantia nigra but not striatum, EXP NEUROL, 161(2), 2000, pp. 638-646
In vivo and in vitro vulnerability of dopaminergic neurons to energy impairment: Role of oxidative stress and dopamine
Authors: Zeevalk, GD Moy, LY Sonsalla, PK
Citation: Gd. Zeevalk et al., In vivo and in vitro vulnerability of dopaminergic neurons to energy impairment: Role of oxidative stress and dopamine, RRD NEUROCH, 3, 2000, pp. 175-190
Risultati: 1-10 |